“…However it is well known that neonatal anti-Xa assays are prone to fluctuating results, with only 27% being within the desired therapeutic range in one study and yet, despite this, efficacy appears to be unaffected (Lulic-Botica et al, 2012). Heparin resistance can be addressed by further increases in dose or, if this strategy fails, by replacing ATIII by infusions of fresh frozen plasma; one paper described five neonates who received ATIII concentrate with good effect (Manco-Johnson, 2006).…”